This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by McClelland, R. A. Articles by Coombes, R. C. Search for Related Content PubMed PubMed Citation Articles by McClelland, R. A. Articles by Coombes, R. C.

Immunocytochemical Assay for Estrogen Receptor: Relationship to Outcome of Therapy in Patients with Advanced Breast Cancer¹

Ludwig Institute for Cancer Research (London Branch) [R. A. M., U. B., R. C. C.], Royal Marsden Hospital [T. J. P., R. C. C.], Sutton, Surrey, SM2 5PX, United Kingdom; Abbott Laboratories, Diagnostics Division, North Chicago, Illinois [L. S. M.]; and Ludwig Institute for Cancer Research, Stadelhoferstrasse 22, 8001 Zurich, Switzerland [E. V. J.]

We have used an immunoperoxidase technique utilizing a monoclonal antibody to the estradiol receptor to identify immunoreactive estradiol receptor in breast carcinomas and have examined the relationship between the immunoreactive estradiol receptor and response to therapy in patients with advanced breast cancer.

Fifty-six patients were found to be assessable for response to endocrine therapy. Twenty-two showed an objective response to some form of endocrine manipulation, and all these had positively stained carcinomas. None of the 17 patients with negatively stained carcinomas responded to endocrine therapy.

We conclude that the monoclonal antibody to estradiol receptor can help identify breast cancer patients who may respond to endocrine therapy.